This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Neurotherapeutics Open Access 30 January 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Xu J et al. Nat Med 2002; 8: 600–606.
Polymeropoulos MH et al. Science 1997; 276: 2045–2047.
Spillantini MG et al. Nature 1997; 388: 839–840.
Giasson BI et al. Science 2000; 290: 985–989.
Cabin DE et al. J Neurosci 2002; 22: 8797–8800.
Lashuel HA et al. Nature 2002; 418: 291.
Krüger R et al. Trends Mol Med 2002; 8: 236–240.
McNaught KS, Jenner P . Neurosci Lett 2001; 297: 191–194.
Junn E, Mouradian MM . Neuroscience Letters 2002; 320: 146–150.
Conway KA et al. Science 2001; 294: 1346–1349.
Weingarten P, Zhou QY . J Neurochem 2001; 77: 776–785.
Lotharius J et al. J Biol Chem 2002; 277: 38884–38894.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chesselet, MF. Dopamine and Parkinson's disease: is the killer in the house?. Mol Psychiatry 8, 369–370 (2003). https://doi.org/10.1038/sj.mp.4001289
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4001289
This article is cited by
-
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Neurotherapeutics (2023)
-
A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (“Line 61”) Mice
Neurotherapeutics (2012)
-
Development of an In Vitro Model to Evaluate the Regenerative Capacity of Adult Brain-Derived Tyrosine Hydroxylase-Expressing Dopaminergic Neurons
Neurochemical Research (2011)
-
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra
Acta Neuropathologica (2006)